Mimetic Medicines' peptide reduces pain-related sodium channels in mice, offering new neuropathic pain strategy

Researchers at Mimetic Medicines tested a short lipidated peptide (SLiP) in mice and found it lowered the presence of Nav1.8 sodium channels on sensory neuron membranes. Reducing these channels helped curb the hyperexcitability that drives neuropathic pain signals.

The study, published in Cell Reports Medicine, showed that the peptide interferes with the interaction that normally maintains Nav1.8 levels, effectively acting as a “bait molecule.” This approach differs from the current focus on psychedelic compounds for pain relief.

Mimetic’s chief scientific officer highlighted Nav1.8 as a still‑under‑exploited target for chronic pain, suggesting the findings lay groundwork for further development beyond existing strategies.